Natixis Advisors
LXRX icon

Natixis Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Natixis Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-86,094
Closed -$207K – 1610
2024
Q1 		$207K Buy
+86,094
New +$185K ﹤0.01% 1518
2023
Q3 		– Sell
-87,425
Closed -$200K – 1514
2023
Q2 		$200K Sell
87,425
-80
-0.1% -$212 ﹤0.01% 1468
2023
Q1 		$213K Buy
+87,505
New +$201K ﹤0.01% 1455
2022
Q4 		– Sell
-88,411
Closed -$212K – 1486
2022
Q3 		$212K Buy
+88,411
New +$245K ﹤0.01% 1432
2022
Q1 		– Sell
-93,969
Closed -$370K – 1450
2021
Q4 		$370K Sell
93,969
-568
-0.6% -$2.76K ﹤0.01% 1291
2021
Q3 		$455K Sell
94,537
-208
-0.2% -$854 ﹤0.01% 1223
2021
Q2 		$435K Sell
94,745
-114
-0.1% -$549 ﹤0.01% 1227
2021
Q1 		$556K Sell
94,859
-6,134
-6% -$42.5K ﹤0.01% 1153
2020
Q4 		$345K Buy
+100,993
New +$193K ﹤0.01% 1165

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Natixis Advisors's LXRX Position: Q2 2024 in Review

Natixis Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2024, closing a stake of 86,094 shares — an estimated $207K sold.

Natixis Advisors first reported a position in LXRX in Q4 2020 and held it in 9 quarters. The position peaked at $556K in Q1 2021. 127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.

  • Natixis Advisors reported no remaining Lexicon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Natixis Advisors sold 86,094 Lexicon Pharmaceuticals shares in Q2 2024, an estimated $207K.
  • Natixis Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Natixis Advisors's Lexicon Pharmaceuticals position peaked at $556K in Q1 2021.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.

Based on Natixis Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.